Commercialising leukemia and lymphoma therapies - future challenges
Allogeneic transplant in multiple myeloma: who should receive it and the future of transplant
Heinz Ludwig et al.
Using cell mass to determine response to treatment: A possible cure?
ASH 2017 top picks: Phase III trials, antibody-drug conjugates and CAR T-cells
Targeted Antibody Mogamulizumab Superior to Vorinostat for Previously Treated CTCL
Youn H. Kim